参考文献
1. Guideline, O. E. C. D. 428-Guideline f or the Testing of Chemicals-Skin Absorption: in vitro Method." Organization for Economic Cooperation and Development, Paris (2004)
2. Oh, Luke, et al. In Vitro Skin Permeation Methodology for Over-The-Counter Topical Dermatologic Products." Therapeutic Innovation & regulatory science 54.3 (2020): 693-700
3. Haq, Anika, et al. Strat-M ® synthetic membrane: Permeability comparison to human cadaver skin.' International journal of pharmaceutics547.1-2 (2018): 432-437
4. Kim, J.S., Mitchell, S., Kijek, P., Tsume, Y., Hilfinger, J. and Amidon, G.L., 2006. The suitability of an in-situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Molecular Pharmaceutics, 3 (6), pp.686-694
5. Chiou, W.L. and Barve, A., 1998. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharmaceutical Research, 15 (11), p.1792
6. Cao, X., Gibbs, S.T., Fang, L., Miller, H.A., Landowski, C.P., Shin, H.C., Lennernas, H., Zhong, Y., Amidon, G.L., Lawrence, X.Y. and Sun, D., 2006. Why is it challenging to predict intestinal drug absorption and oral bioavailability in humans using the rat model. Pharmaceutical Research, 23 (8), pp.1675-168
7. Salphati, L., Childers, K., Pan, L., Tsutsui, K. and Takahashi, L., 2001. Evaluation of a single-pass intestinal perfusion method in rats for the prediction of absorption in man. Journal of pharmacy and pharmacology, 53 (7), pp.1007-1013
8. Dahlgren, D., Roos, C., Sjögren, E. and Lennernäs, H., 2015. Direct in vivo human intestinal permeability (Peff) determination with different clinical perfusion and intubation methods. Journal of pharmaceutical sciences, 104 (9), pp.2702-2726
9. Technical Guidelines for Non-clinical Kinetic Studies of Chemical Drugs
10. Diehl. K et al. " A Good Practice Guide to the Administration of Substances and Removal of Blood, Including Routes and Volume. " Journal of Applied Toxicology. 21: 15-23. 2001
11. Turner P.V., Brabb T. Pekow C., and Vasbinder M.A ". Administration of Substances to Laboratory Animals: Routes of Administration and Factors to Consider. " JAALAS. 50 (5): 600-613. 2011
12. Rollin B.E., Kesel M.L., The experimental animal in biomedical research, Vol. 2. Care, husbandry, and well-being, an overview by species
13. Maurer TS, DeBartolo DB, Tess DA, Scott DO (2005) Relationship between exposure and non-specific thirty-binding of three central nervous system drugs in mice. Drug Metab Dispos 33:175-181
14. Liu X, et al. (2009) Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787-793
15. Gilberto DB, Zeoli AH, Szczerba PJ, Gehret JR, Holahan MA, Sitko GR, Johnson CA, Cook JJ, Motzel SL. Contemp Top Lab Anim Sci. 2003 Jul; 42 (4): 53-9
16. Seshadri Neer Vannan. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin. Drug Metab. Toxicol. (2006) 2 (5): 715-731
17. Michael J Waring. Lipophilicity in drug discovery. Expert Opin. Drug Discov. (2010) 5 (3)
18. Dai W -G, Pollock-Dove C, Dong L C, Li S. Advanced screening assays to rapidly identify solubility-enhancing formulations: high throughput, miniaturization, and automation. Adv Drug Deliv Rev. 2008; 60 (6): 657 72
19. Hywel D. Williams, Natalie L. Strategies to Address Low Drug Solubility in Discovery and Development. Pharmacol Rev 65:315 499, January 2013